COVID-19 Response

Latest Updates: As of April 5, 2022, Sotrovimab is no longer authorized to treat COVID-19 in any US region due to increases in cases caused by the Omicron BA.2 sub-variant. The nationwide Test to Treat initiative has been launched in March 2022, and the Test to Treat locator map can help you find a site near you.  


Last Updated 4/11/22

Treatments to prevent severe COVID-19

Several treatments are available to treat patients who are already diagnosed with COVID-19. Also known as COVID-19 therapeutics, these treatments commonly fall under three categories: Monoclonal antibodies (mAbs), antivirals, and convalescent plasma.  

Treatment before severe illness is critical in preventing hospitalization from COVID-19.  Learn how antibody treatments within the first 10 days of symptoms can help prevent severe outcomes from COVID-19:


What are COVID-19 Therapeutics?

COVID-19 therapeutics are treatments for patients who test positive for COVID-19 and may prevent COVID-19 transmission among adults and pediatric individuals who have been exposed to COVID-19. Individuals that have been exposed to COVID-19 and are at high risk of progressing to severe COVID-19 are also eligible to receive certain types of therapeutics authorized for post-exposure prophylaxis (PEP) to prevent COVID-19. There are several categories of COVID-19 therapeutics currently available to treat patients. Among them: 

  • Antibody Products – Includes monoclonal antibodies (mAbs) that can be administered via infusion or subcutaneous injection. 
  • Antiviral Products – Includes recently available oral options


Key Resources For COVID-19 Therapeutics 

To keep up-to-date with the latest information on patient eligibility and treatment guidelines, visit the NIH’s guide for COVID-19 Treatment Guidelines.

Additional Resources

For Patients
  • Test to Treat locator map to find local clinics, doctors, and pharmacies that are carrying COVID-19 medications. 
  • www.combatcovid.hhs.gov – How mAbs work, patient eligibility, and where to sign up, what you can expect when getting treatment.  
  • Cost of mAbs – mAbs for COVID-19 are available at no cost to patients on Medicare, regardless of immigration status. Healthcare facilities may ask for insurance details to bill your insurance company for administering the treatment if you have Medicaid or private insurance.
For Providers

Antibody Products

Antibody products used to treat COVID-19 include: 

  • Monoclonal antibodies (mAbs) 
  • COVID-19 Convalescent Plasma
  • Anti-SARS-CoV-2 Specific Immunoglobulin

Of the antibody types listed above, mAbs are the only therapeutic type currently recommended by the COVID-19 Treatment Panel of the National Institutes of Health to treat outpatients with mild to moderate COVID-19 who are at high risk for severe outcomes. Treatment of non-hospitalized patients with COVID-19 convalescent plasma or SARS-CoV-2 Specific immunoglobulins is not yet recommended. Learn more here.  

Monoclonal Antibodies (mAbs)

mAbs for COVID-19 are designed to block viral attachment and entry of the virus that causes COVID-19, thus neutralizing the virus. Patients who have been exposed to or may have COVID-19 and are not yet hospitalized may be eligible for treatment.

Patients must have a prescription from a healthcare provider in order to receive treatment. Learn more about mAbs for treating COVID-19 at the links below.

As of April 6, 2022, there are two mAbs therapies available for the prevention or treatment of mild-moderate COVID-19 through FDA Emergency Use Authorization (EUA):

  • Evusheld (AstraZeneca) – preventive (PrEP)
  • Bebtelovimab (Eli Lilly) – treatment 

Previously used mAbs are not likely to be effective against the Omicron variant and BA.2 subvariant, and are not currently authorized in the US. More patient information can be found in the FDA Fact sheets for Evusheld and Bebtelovimab, and the HHS side-by-side overview of outpatient therapies authorized for treatment of mild-moderate COVID-19. 

Convalescent Plasma for Hospitalized Patients

COVID-19 convalescent plasma is human plasma collected from individuals whose plasma contains anti-SARS-CoV-2 antibodies and meets donor eligibility requirements. Hospitalized patients with COVID-19 may improve faster if they receive plasma from those who have recovered from COVID-19 early in the course of disease, because it may have the ability to fight the virus that causes COVID-19.

  • On August 23, 2020, the FDA issued an EUA for COVID-19 convalescent plasma for the treatment of hospitalized patients with COVID-19. This treatment is only available to be administered in a hospital setting or clinical trial.
  • For information on clinical trials that are testing the use of COVID-19 convalescent plasma for COVID-19, please see www.clinicaltrials.gov.
Anti-SARS-CoV-2 Specific Immunoglobulin

There are currently no clinical data on the use of immunoglobulins in treating patients. Trials are in development but not yet enrolling participants. 


Antiviral Products

Antiviral therapeutics works to inhibit the replication of viruses in our bodies by stopping messenger RNA from relaying instructions to keep producing the genetic material needed for a virus to survive. 

Oral Antivirals

Oral antivirals are the first treatment for COVID-19 that is in the form of a pill that is taken orally, making antiviral treatment more accessible to patients who are at high risk for progression to severe COVID-19. As of December 23, 2021, there are two oral antivirals available for the treatment of mild-moderate COVID-19 through FDA Emergency Use Authorization (EUA):

  • PAXLOVID® (Pfizer)
  • Lagevrio (Merck)

More patient information can be found in the FDA Fact sheets for PAXLOVID® and Lagevrio, and the HHS side-by-side overview of outpatient therapies authorized for treatment of mild-moderate COVID-19. Test to treat options are becoming more available. Check out the Test to Treat locator map to see where you can find treatment options near you. 

IV Antivirals

Remdesivir, commercially known as VEKLURY (Gilead Sciences) is an antiviral drug that was approved by the FDA on October 22, 2020 for the treatment of COVID-19. This treatment is only available to be administered in a hospital setting through an intravenous infusion. 

Patient information can be found in the FDA Fact sheet here. For more information, visit the FDA’s frequently asked questions page for remdesivir here, or visit Gilead’s resource center for healthcare providers.